b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">27664318</PMID>\n        <DateCompleted>\n            <Year>2017</Year>\n            <Month>07</Month>\n            <Day>04</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>12</Month>\n            <Day>02</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1096-0295</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>81</Volume>\n                    <PubDate>\n                        <Year>2016</Year>\n                        <Month>Nov</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Regulatory toxicology and pharmacology : RTP</Title>\n                <ISOAbbreviation>Regul. Toxicol. Pharmacol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Methyl isobutyl ketone-induced hepatocellular carcinogenesis in B6C3F<sub>1</sub> mice: A constitutive androstane receptor (CAR)-mediated mode of action.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>421-429</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0273-2300(16)30272-0</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yrtph.2016.09.024</ELocationID>\n            <Abstract>\n                <AbstractText>In a National Toxicology Program (NTP) chronic inhalation study with methyl isobutyl ketone (MIBK), increases in hepatocellular adenomas and hepatocellular adenomas and carcinomas (combined) were observed in male and female B6C3F<sub>1</sub> mice at 1800\xc2\xa0ppm. A DNA reactive Mode-of-Action (MOA) for this liver tumor response is not supported by the evidence as MIBK and its major metabolites lack genotoxicity in both in\xc2\xa0vitro and in\xc2\xa0vivo studies. Constitutive androstane receptor (CAR) nuclear receptor-mediated activation has been hypothesized as the MOA for MIBK-induced mouse liver tumorigenesis. To further investigate the MOA for MIBK-induced murine liver tumors, male and female B6C3F1, C57BL/6, and CAR/PXR Knockout (KO) mice were exposed to either 0 or 1800\xc2\xa0ppm MIBK for 6\xc2\xa0h/day, 5 days/week for a total of 10 days. On day 1, mice were implanted with osmotic mini-pumps containing 5-Bromo-2-deoxyuridine (BrdU) 1\xc2\xa0h following exposure and humanely euthanized 1-3\xc2\xa0h following the final exposure. B6C3F<sub>1</sub> and C57BL/6 mice had statistically significant increases in liver weights compared to controls that corresponded with hepatocellular hypertrophy and increased mitotic figures. Hepatocellular proliferation data indicated induction of S-phase DNA synthesis in B6C3F<sub>1</sub> and C57BL/6 mice exposed to 1800\xc2\xa0ppm MIBK compared to control, and no increase was observed in MIBK exposed CAR/PXR KO mice. Liver gene expression changes indicated a maximally-induced Cyp2b10 (CAR-associated) transcript and a slight increase in Cyp3a11(PXR-associated) transcript in B6C3F<sub>1</sub> and C57BL/6 mice exposed to 1800\xc2\xa0ppm MIBK compared to controls, but not in Cyp1a1 (AhR-associated) or Cyp4a10 (PPAR-\xce\xb1-associated) transcripts. CAR/PXR KO mice exposed to 1800\xc2\xa0ppm MIBK showed no evidence of activation of AhR, CAR, PXR or PPAR-\xce\xb1 nuclear receptors via their associated transcripts. MIBK induced hepatic effects are consistent with a phenobarbital-like MOA where the initiating events are activation of the CAR and PXR nuclear receptors and resultant hepatocellular proliferation leading to rodent liver tumors.</AbstractText>\n                <CopyrightInformation>Copyright \xc3\x82\xc2\xa9 2016 Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Hughes</LastName>\n                    <ForeName>B J</ForeName>\n                    <Initials>BJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The Dow Chemical Company, Midland, MI, USA. Electronic address: bhughes2@dow.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Thomas</LastName>\n                    <ForeName>J</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The Dow Chemical Company, Midland, MI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lynch</LastName>\n                    <ForeName>A M</ForeName>\n                    <Initials>AM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>American Chemistry Council, Washington, DC, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Borghoff</LastName>\n                    <ForeName>S J</ForeName>\n                    <Initials>SJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>ToxStrategies, Cary, NC, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Green</LastName>\n                    <ForeName>S</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Eastman Chemical, Kingsport, TN, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mensing</LastName>\n                    <ForeName>T</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Sasol Solvents, Moers, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sarang</LastName>\n                    <ForeName>S S</ForeName>\n                    <Initials>SS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Shell International, Houston, TX, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>LeBaron</LastName>\n                    <ForeName>M J</ForeName>\n                    <Initials>MJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>The Dow Chemical Company, Midland, MI, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2016</Year>\n                <Month>09</Month>\n                <Day>21</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>Regul Toxicol Pharmacol</MedlineTA>\n            <NlmUniqueID>8214983</NlmUniqueID>\n            <ISSNLinking>0273-2300</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018160">Receptors, Cytoplasmic and Nuclear</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>438XLITDI3</RegistryNumber>\n                <NameOfSubstance UI="C409467">constitutive androstane receptor</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>6QDY60NH6N</RegistryNumber>\n                <NameOfSubstance UI="D008742">Methyl n-Butyl Ketone</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>U5T7B88CNP</RegistryNumber>\n                <NameOfSubstance UI="C005458">methyl isobutyl ketone</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019570" MajorTopicYN="N">Inhalation Exposure</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008742" MajorTopicYN="N">Methyl n-Butyl Ketone</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018160" MajorTopicYN="N">Receptors, Cytoplasmic and Nuclear</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">BrdU labeling</Keyword>\n            <Keyword MajorTopicYN="N">CAR/PXR</Keyword>\n            <Keyword MajorTopicYN="N">Knockout mice</Keyword>\n            <Keyword MajorTopicYN="N">Mode of action</Keyword>\n            <Keyword MajorTopicYN="N">Rodent liver</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2016</Year>\n                <Month>01</Month>\n                <Day>06</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2016</Year>\n                <Month>08</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2016</Year>\n                <Month>09</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2016</Year>\n                <Month>10</Month>\n                <Day>30</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2017</Year>\n                <Month>7</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2016</Year>\n                <Month>9</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">27664318</ArticleId>\n            <ArticleId IdType="pii">S0273-2300(16)30272-0</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.yrtph.2016.09.024</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'